Fasoracetam

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326935

CAS#: 110958-19-5

Description: Fasoracetam, also known as NS-105; NFC-1; LAM-105, is a GABA receptor modulator potentially for the treatment of attention deficit hyperactivity disorder. It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder. In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity. In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist and upregulated production of GABAB receptors after repeat dosing.


Price and Availability

Size
Price

Size
Price

Size
Price

Fasoracetam is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 326935
Name: Fasoracetam
CAS#: 110958-19-5
Chemical Formula: C10H16N2O2
Exact Mass: 196.1212
Molecular Weight: 196.25
Elemental Analysis: C, 61.20; H, 8.22; N, 14.27; O, 16.30


Related CAS #: 1618109-51-5 (tartrate)   2055646-53-0 (hydrate)   110958-19-5    

Synonym: Fasoracetam; N-(5-Oxo-D-prolyl)piperidine; NS-105; NFC-1; LAM-105.

IUPAC/Chemical Name: (R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine

InChi Key: GOWRRBABHQUJMX-MRVPVSSYSA-N

InChi Code: InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1

SMILES Code: O=C(N1CCCCC1)[C@@H](CC2)NC2=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Chugh G, Asghar M, Patki G, Bohat R, Jafri F, Allam F, Dao AT, Mowrey C, Alkadhi K, Salim S. A high-salt diet further impairs age-associated declines in cognitive, behavioral, and cardiovascular functions in male Fischer brown Norway rats. J Nutr. 2013 Sep;143(9):1406-13. doi: 10.3945/jn.113.177980. Epub 2013 Jul 17. PubMed PMID: 23864508; PubMed Central PMCID: PMC3743272.

2: Fasoracetam. LAM 105, NS 105. Drugs R D. 1999 Aug;2(2):135-6. PubMed PMID: 10820660.

3: Mukai H, Sugimoto T, Ago M, Morino A, Takaichi M, Ogawa Y, Seki H, Matsuura C, Esumi Y. Pharmacokinetics of NS-105, a novel cognition enhancer. 2nd communication: distribution and transfer into fetus and milk after single administration, and effects of repeated administration on pharmacokinetics and hepatic drug-metabolizing enzyme activities in rats. Arzneimittelforschung. 1999 Dec;49(12):977-85. PubMed PMID: 10635441.

4: Hirouchi M, Oka M, Itoh Y, Ukai Y, Kimura K. Role of metabotropic glutamate receptor subclasses in modulation of adenylyl cyclase activity by a nootropic NS-105. Eur J Pharmacol. 2000 Jan 3;387(1):9-17. PubMed PMID: 10633154.

5: Mukai H, Sugimoto T, Ago M, Morino A. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105. Arzneimittelforschung. 1999 Nov;49(11):881-90. PubMed PMID: 10604039.

6: Ogasawara T, Itoh Y, Tamura M, Mushiroi T, Ukai Y, Kise M, Kimura K. Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer. Pharmacol Biochem Behav. 1999 Sep;64(1):41-52. PubMed PMID: 10494996.

7: Kumagai Y, Yokota S, Isawa S, Murasaki M, Mukai H, Miyatake S. Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects. Int J Clin Pharmacol Res. 1999;19(1):1-8. PubMed PMID: 10450537.

8: Shimidzu T, Itoh Y, Oka M, Ishima T, Ukai Y, Yoshikuni Y, Kimura K. Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment. Eur J Pharmacol. 1997 Nov 12;338(3):225-32. PubMed PMID: 9424016.

9: Oka M, Itoh Y, Tatsumi S, Ma FH, Ukai Y, Yoshikuni Y, Kimura K. A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture. Naunyn Schmiedebergs Arch Pharmacol. 1997 Aug;356(2):189-96. PubMed PMID: 9272724.

10: Oka M, Itoh Y, Shimidzu T, Ukai Y, Yoshikuni Y, Kimura K. Involvement of metabotropic glutamate receptors in Gi- and Gs-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain. Brain Res. 1997 Apr 18;754(1-2):121-30. PubMed PMID: 9134967.

11: White RL. Review of current status of cochlear prostheses. IEEE Trans Biomed Eng. 1982 Apr;29(4):233-8. PubMed PMID: 6896043.